Simultaneous targeting of EGFR, HER2, and HER4 by afatinib overcomes intrinsic and acquired cetuximab resistance in head and neck squamous cell carcinoma cell lines
出版年份 2018 全文链接
标题
Simultaneous targeting of EGFR, HER2, and HER4 by afatinib overcomes intrinsic and acquired cetuximab resistance in head and neck squamous cell carcinoma cell lines
作者
关键词
-
出版物
Molecular Oncology
Volume 12, Issue 6, Pages 830-854
出版商
Wiley
发表日期
2018-03-31
DOI
10.1002/1878-0261.12197
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- Phase I study of induction chemotherapy with afatinib, ribavirin, and weekly carboplatin and paclitaxel for stage IVA/IVB human papillomavirus-associated oropharyngeal squamous cell cancer
- (2017) Lara A. Dunn et al. HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK
- How Standard Is Second-Line Cetuximab in Recurrent or Metastatic Head and Neck Cancer in 2017?
- (2017) Petr Szturz et al. JOURNAL OF CLINICAL ONCOLOGY
- The role of anti-EGFR agents in patients with locoregionally advanced head and neck cancer: a meta-analysis of randomized trials
- (2017) Bum Jun Kim et al. Oncotarget
- AKT can modulate the in vitro response of HNSCC cells to irreversible EGFR inhibitors
- (2017) Renato José Silva-Oliveira et al. Oncotarget
- Afatinib radiosensitizes head and neck squamous cell carcinoma cells by targeting cancer stem cells
- (2017) Muzafar A. Macha et al. Oncotarget
- Epidermal Growth Factor Receptor Cell Proliferation Signaling Pathways
- (2017) et al. Cancers
- Epidermal Growth Factor Receptor Inhibitors: Coming of Age
- (2017) Amit Mahipal et al. Cancer Control
- APR-246 (PRIMA-1 MET ) strongly synergizes with AZD2281 (olaparib) induced PARP inhibition to induce apoptosis in non-small cell lung cancer cell lines
- (2016) Christophe Deben et al. CANCER LETTERS
- HER2 and HER3 in HPV+ and HPV- HNSCC--Letter
- (2016) J.-P. Machiels et al. CLINICAL CANCER RESEARCH
- Antitumor Activity of Pembrolizumab in Biomarker-Unselected Patients With Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma: Results From the Phase Ib KEYNOTE-012 Expansion Cohort
- (2016) Laura Q.M. Chow et al. JOURNAL OF CLINICAL ONCOLOGY
- Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): an open-label, multicentre, phase 1b trial
- (2016) Tanguy Y Seiwert et al. LANCET ONCOLOGY
- Targeting the HER Family with Pan-HER Effectively Overcomes Resistance to Cetuximab
- (2016) M. Iida et al. MOLECULAR CANCER THERAPEUTICS
- EGFR and RB1 as Dual Biomarkers in HPV-Negative Head and Neck Cancer
- (2016) T. N. Beck et al. MOLECULAR CANCER THERAPEUTICS
- Co-treatment of wild-type EGFR head and neck cancer cell lines with afatinib and cisplatin
- (2016) ROMAN C. BRANDS et al. Molecular Medicine Reports
- Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck
- (2016) Robert L. Ferris et al. NEW ENGLAND JOURNAL OF MEDICINE
- A phase I study afatinib/carboplatin/paclitaxel induction chemotherapy followed by standard chemoradiation in HPV-negative or high-risk HPV-positive locally advanced stage III/IVa/IVb head and neck squamous cell carcinoma
- (2016) Christine H. Chung et al. ORAL ONCOLOGY
- Preclinical and clinical studies on afatinib in monotherapy and in combination regimens: Potential impact in colorectal cancer
- (2016) I. De Pauw et al. PHARMACOLOGY & THERAPEUTICS
- Randomized Phase II Study of Duligotuzumab (MEHD7945A) vs. Cetuximab in Squamous Cell Carcinoma of the Head and Neck (MEHGAN Study)
- (2016) Jérôme Fayette et al. Frontiers in Oncology
- Increased Expression of HER2, HER3, and HER2:HER3 Heterodimers in HPV-Positive HNSCC Using a Novel Proximity-Based Assay: Implications for Targeted Therapies
- (2015) N. I. Pollock et al. CLINICAL CANCER RESEARCH
- Afatinib versus methotrexate as second-line treatment in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck progressing on or after platinum-based therapy (LUX-Head & Neck 1): an open-label, randomised phase 3 trial
- (2015) Jean-Pascal H Machiels et al. LANCET ONCOLOGY
- Afatinib efficacy against squamous cell carcinoma of the head and neck cell lines in vitro and in vivo
- (2015) Natalie R. Young et al. Targeted Oncology
- Afatinib, an Irreversible EGFR Family Inhibitor, Shows Activity Toward Pancreatic Cancer Cells, Alone and in Combination with Radiotherapy, Independent of KRAS Status
- (2015) Florence Huguet et al. Targeted Oncology
- A randomized, phase II study of afatinib versus cetuximab in metastatic or recurrent squamous cell carcinoma of the head and neck†
- (2014) T. Y. Seiwert et al. ANNALS OF ONCOLOGY
- Overcoming cetuximab resistance in HNSCC: The role of AURKB and DUSP proteins
- (2014) Carolien Boeckx et al. CANCER LETTERS
- Integrative and Comparative Genomic Analysis of HPV-Positive and HPV-Negative Head and Neck Squamous Cell Carcinomas
- (2014) Tanguy Y. Seiwert et al. CLINICAL CANCER RESEARCH
- Overcoming acquired resistance to cetuximab by dual targeting HER family receptors with antibody-based therapy
- (2014) Mari Iida et al. Molecular Cancer
- Impact of human papilloma virus infection on the response of head and neck cancers to anti-epidermal growth factor receptor antibody therapy
- (2014) M Pogorzelski et al. Cell Death & Disease
- Treatment with a combination of the ErbB (HER) family blocker afatinib and the IGF-IR inhibitor, NVP-AEW541 induces synergistic growth inhibition of human pancreatic cancer cells
- (2013) Nikolaos Ioannou et al. BMC CANCER
- Current challenges and clinical investigations of epidermal growth factor receptor (EGFR)- and ErbB family-targeted agents in the treatment of head and neck squamous cell carcinoma (HNSCC)
- (2013) Roger B. Cohen CANCER TREATMENT REVIEWS
- Statistical analysis of human papillomavirus in a subset of upper aerodigestive tract tumors
- (2013) Hongwei Liu et al. JOURNAL OF MEDICAL VIROLOGY
- Anti-Epidermal Growth Factor Receptor Therapy in Head and Neck Squamous Cell Carcinoma: Focus on Potential Molecular Mechanisms of Drug Resistance
- (2013) C. Boeckx et al. ONCOLOGIST
- Treatment response of HPV-positive and HPV-negative head and neck squamous cell carcinoma cell lines
- (2013) Remco Nagel et al. ORAL ONCOLOGY
- The Intriguing Interplay Between Therapies Targeting the Epidermal Growth Factor Receptor, the Hypoxic Microenvironment and Hypoxia-inducible Factors
- (2012) An Wouters et al. CURRENT PHARMACEUTICAL DESIGN
- Predictive value of epidermal growth factor receptor expression for first-line chemotherapy plus cetuximab in patients with head and neck and colorectal cancer: Analysis of data from the EXTREME and CRYSTAL studies
- (2012) Lisa Licitra et al. EUROPEAN JOURNAL OF CANCER
- Prevalence of human papillomavirus in oropharyngeal and nonoropharyngeal head and neck cancer-systematic review and meta-analysis of trends by time and region
- (2012) Hisham Mehanna et al. HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK
- Cetuximab-mediated Tumor Regression Depends on Innate and Adaptive Immune Responses
- (2012) Xuanming Yang et al. MOLECULAR THERAPY
- Comparative Analysis of Dynamic Cell Viability, Migration and Invasion Assessments by Novel Real-Time Technology and Classic Endpoint Assays
- (2012) Ridha Limame et al. PLoS One
- Dual Kinase Inhibition of EGFR and HER2 Overcomes Resistance to Cetuximab in a NovelIn VivoModel of Acquired Cetuximab Resistance
- (2011) Kelly M. Quesnelle et al. CLINICAL CANCER RESEARCH
- Membranous expression of Her3 is associated with a decreased survival in head and neck squamous cell carcinoma
- (2011) Mikiko Takikita et al. Journal of Translational Medicine
- Activation of ERBB2 Signaling Causes Resistance to the EGFR-Directed Therapeutic Antibody Cetuximab
- (2011) K. Yonesaka et al. Science Translational Medicine
- Evaluation of EGFR gene copy number as a predictive biomarker for the efficacy of cetuximab in combination with chemotherapy in the first-line treatment of recurrent and/or metastatic squamous cell carcinoma of the head and neck: EXTREME study
- (2010) L. Licitra et al. ANNALS OF ONCOLOGY
- The Epidermal Growth Factor Receptor Antibody Cetuximab Induces Autophagy in Cancer Cells by Downregulating HIF-1 and Bcl-2 and Activating the Beclin 1/hVps34 Complex
- (2010) X. Li et al. CANCER RESEARCH
- HIF-2 -mediated activation of the epidermal growth factor receptor potentiates head and neck cancer cell migration in response to hypoxia
- (2010) X. Wang et al. CARCINOGENESIS
- Combination of Anti-IGF-1R Antibody A12 and Ionizing Radiation in Upper Respiratory Tract Cancers
- (2010) Oliver Riesterer et al. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
- HPV-associated head and neck cancer: a virus-related cancer epidemic
- (2010) Shanthi Marur et al. LANCET ONCOLOGY
- Epithelial-to-mesenchymal transition and c-myc expression are the determinants of cetuximab-induced enhancement of squamous cell carcinoma radioresponse
- (2010) Ira Skvortsova et al. RADIOTHERAPY AND ONCOLOGY
- Chemoradiation interactions under reduced oxygen conditions: Cellular characteristics of an in vitro model
- (2009) An Wouters et al. CANCER LETTERS
- Factors associated with clinical benefit from epidermal growth factor receptor inhibitors in recurrent and metastatic squamous cell carcinoma of the head and neck
- (2009) Ezra Eddy Wyssam Cohen et al. ORAL ONCOLOGY
- Signal integration: a framework for understanding the efficacy of therapeutics targeting the human EGFR family
- (2008) H. Michael Shepard et al. JOURNAL OF CLINICAL INVESTIGATION
- Requirement of hypoxia-inducible factor-1 down-regulation in mediating the antitumor activity of the anti-epidermal growth factor receptor monoclonal antibody cetuximab
- (2008) X. Li et al. MOLECULAR CANCER THERAPEUTICS
- Platinum-Based Chemotherapy plus Cetuximab in Head and Neck Cancer
- (2008) Jan B. Vermorken et al. NEW ENGLAND JOURNAL OF MEDICINE
- Mechanisms of acquired resistance to cetuximab: role of HER (ErbB) family members
- (2008) D L Wheeler et al. ONCOGENE
- BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models
- (2008) D Li et al. ONCOGENE
Become a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get StartedAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started